Imperial College London
Portrait Picture

Peter Openshaw - Professor of Experimental Medicine

Faculty of Medicine, National Heart & Lung Institute

Proconsul, Professor of Experimental Medicine
 
 
 
//

Contact

 

+44 (0)20 7594 3854p.openshaw Website CV

 
 
//

Assistant

 

Ms Gale Lewis +44 (0)20 7594 0944

 
//

Location

 

353Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Coultas:2019:10.1136/thoraxjnl-2018-212212,
author = {Coultas, JA and Smyth, R and Openshaw, PJ},
doi = {10.1136/thoraxjnl-2018-212212},
journal = {Thorax},
pages = {986--993},
title = {Respiratory syncytial virus (RSV): a scourge from infancy to old age},
url = {http://dx.doi.org/10.1136/thoraxjnl-2018-212212},
volume = {74},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Respiratory syncytial virus (RSV) is the most common single cause of respiratory hospitalisation of infants and is the second largest cause of lower respiratory infection mortality worldwide. In adults, RSV is an under-recognised cause of deterioration in health, particularly in frail elderly persons. Infection rates typically rise in late autumn and early winter causing bronchiolitis in infants, common colds in adults and insidious respiratory illness in the elderly. Virus detection methods optimised for use in children have low detection rate in adults, highlighting the need for better diagnostic tests. There are many vaccines under development, mostly based on the surface glycoprotein F which exists in two conformations (prefusion and postfusion). Much of the neutralising antibody appears to be to the prefusion form. Vaccines being developed include live attenuated, subunit, particle based and live vectored agents. Different vaccine strategies may be appropriate for different target populations: at-risk infants, school-age children, adult caregivers and the elderly. Antiviral drugs are in clinical trial and may find a place in disease management. RSV disease is one of the major remaining common tractable challenges in infectious diseases and the era of vaccines and antivirals for RSV is on the near horizon.
AU  - Coultas,JA
AU  - Smyth,R
AU  - Openshaw,PJ
DO  - 10.1136/thoraxjnl-2018-212212
EP  - 993
PY  - 2019///
SN  - 0040-6376
SP  - 986
TI  - Respiratory syncytial virus (RSV): a scourge from infancy to old age
T2  - Thorax
UR  - http://dx.doi.org/10.1136/thoraxjnl-2018-212212
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000487508000011&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://thorax.bmj.com/content/74/10/986.info
UR  - http://hdl.handle.net/10044/1/73848
VL  - 74
ER  -
Download